Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Menopausal Remediation and Quality of Life (QoL) Improvement: Insights and Perspectives

Author(s): Sradhanjali Mohapatra, Zeenat Iqbal*, Sayeed Ahmad, Kanchan Kohli, Uzma Farooq, Santwana Padhi, Mariya Kabir and Ayash K. Panda

Volume 20, Issue 10, 2020

Page: [1624 - 1636] Pages: 13

DOI: 10.2174/1871530320666200730225830

Price: $65

Abstract

Cessation of menstruation, widely known as menopause is a significant transition period in women’s life. It leads to the arrest of fertility and creates a depletion of the hormones causing physical, mental, sexual, and social problems which lead to a serious decline in their quality of life. The onset of menopause induces certain sudden changes, while others appear in a phasic manner, henceforth demanding an adequate understanding of its progression, adverse impact on life, and exploration of any remedial measures thereof. Menopause, despite being a natural occurrence, brings in significant changes to women’s life, almost sometimes leading to severe debilitation. However, it is still not attended and remains an ignored health issue that warrants the immediate attention of researchers, practitioners, and health policymakers. The present review is an attempt to draw attention towards these women-centric health issues and diligently explores the causes, symptoms and also describes the various procedures for the management of menopausal and postmenopausal syndromes. The review tries to summarise the currently available pharmaceutical interventions and also dwells into herbal and complementary remedies which could ameliorate and provide respite from the etiolating menopausal symptoms.

Keywords: Menopause, postmenopausal syndrome, quality of life, menopausal management, herbal remedy, scales.

« Previous Next »
Graphical Abstract

[1]
Definition of Menopause | Dictionary.Com, 2020. Available at: Www.Dictionary.Comhttps://www.dictionary.com/browse/menopause (Accessed on April 1, 2019)
[2]
Whiteley, J.; DiBonaventura, Md.; Wagner, J.S.; Alvir, J.; Shah, S. The impact of menopausal symptoms on quality of life, productivity, and economic outcomes. J. Womens Health (Larchmt.), 2013, 22(11), 983-990.
[http://dx.doi.org/10.1089/jwh.2012.3719] [PMID: 24083674]
[3]
Dalal, P.K.; Agarwal, M. Postmenopausal syndrome. Indian J. Psychiatry, 2015, 57(6)(Suppl. 2), S222-S232.
[http://dx.doi.org/10.4103/0019-5545.161483] [PMID: 26330639]
[4]
Natarajan, J.; Seshan, V.; Muliira, R.S. Review literature on distress during the menopausal transition and their impact on the quality of life of women: What is the evidence? IOSR J. Nurs. Health Sci., , 2013, 2(4), 01-10.
[5]
Rezarta, L.; Kamberi, F.; Peto, E. Menopausal symptoms and women’s quality of life outcomes: Literature review. EC Gynaecology, 2017, 6(5), 167-172.
[6]
Brzezinski, A. Menopausal symptoms: not just estrogen deficiency. Menopause, 2019, 26(3), 229-230.
[http://dx.doi.org/10.1097/GME.0000000000001290] [PMID: 30586003]
[7]
Omaima, M. Menopausal transition and its effect on women’s health. Am. J. Sci., 2013, 9(1), 369-379.
[8]
North American Menopause Society, 2004. Available at: www.menopause.org (Accessed on April 1, 2019).
[9]
WHO Scientific Group on Research on the Menopause in the. 1990s. WHO Technical Report Series Geneva; WHO: Switzerland, 1996.
[10]
Contestabile, E.; Derzko, C. Canadian consensus on menopause and perimenopause. J. Obstet. Gynaecol. Can., 2001, 23, 836-841.
[11]
Laughlin, D.; Thorney Croft, I.H. Amenorrhea. In: Current obstetric and gynecologic diagnosis and treatment, 9th ed; DeCherney, A.H.; Nathan, L., Eds.;; McGraw Hill Companies, 2003; pp. 991-1000.
[12]
Okeke, T.; Anyaehie, U.; Ezenyeaku, C. Premature menopause. Ann. Med. Health Sci. Res., 2013, 3(1), 90-95.
[http://dx.doi.org/10.4103/2141-9248.109458] [PMID: 23634337]
[13]
Menopause symptoms and relief. Available at: https://www.womenshealth.gov/menopause/menopause-symptoms-and-relief (Accessed on April 1, 2019).
[14]
Portman, D.J.; Gass, M.L. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause, 2014, 21(10), 1063-1068.
[http://dx.doi.org/10.1097/GME.0000000000000329] [PMID: 25160739]
[15]
Tao, M.; Shao, H.; Li, C.; Teng, Y. Correlation between the modified Kupperman Index and the Menopause Rating Scale in Chinese women. Patient Prefer. Adherence, 2013, 7, 223-229.
[PMID: 23569361]
[16]
Heinemann, L.A.; Potthoff, P.; Schneider, H.P. International versions of the Menopause Rating Scale (MRS). Health Qual. Life Outcomes, 2003, 1, 28.
[http://dx.doi.org/10.1186/1477-7525-1-28] [PMID: 12914663]
[17]
Utian, W.H. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: A comprehensive review. Health Qual. Life Outcomes, 2005, 3, 47.
[http://dx.doi.org/10.1186/1477-7525-3-47] [PMID: 16083502]
[18]
Deecher, D.C. Physiology of thermoregulatory dysfunction and current approaches to the treatment of vasomotor symptoms. Expert Opin. Investig. Drugs, 2005, 14(4), 435-448.
[http://dx.doi.org/10.1517/13543784.14.4.435] [PMID: 15882119]
[19]
Kronenberg, F. Hot flashes: Epidemiology and physiology. Ann. N. Y. Acad. Sci., 1990, 592, 52-86.
[http://dx.doi.org/10.1111/j.1749-6632.1990.tb30316.x] [PMID: 2197954]
[20]
Cody, J.D.; Jacobs, M.L.; Richardson, K.; Moehrer, B.; Hextall, A. Oestrogen therapy for urinary incontinence in post‐menopausal women. Cochrane Database Syst. Rev., 2012, 17(10)CD001405
[http://dx.doi.org/10.1002/14651858.CD001405.pub3]
[21]
Women and Sleep Poll National Sleep Foundation, 1998.
[22]
Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause, 2010, 17(1), 25-54.
[http://dx.doi.org/10.1097/gme.0b013e3181c617e6] [PMID: 20061894]
[23]
Rizzoli, R.; Bischoff-Ferrari, H.; Dawson-Hughes, B.; Weaver, C. Nutrition and bone health in women after the menopause. Womens Health (Lond), 2014, 10(6), 599-608.
[http://dx.doi.org/10.2217/WHE.14.40] [PMID: 25482487]
[24]
Wajchenberg, B.L. Subcutaneous and visceral adipose tissue: Their relation to the metabolic syndrome. Endocr. Rev., 2000, 21(6), 697-738.
[http://dx.doi.org/10.1210/edrv.21.6.0415] [PMID: 11133069]
[25]
Misso, M.L.; Jang, C.; Adams, J.; Tran, J.; Murata, Y.; Bell, R.; Boon, W.C.; Simpson, E.R.; Davis, S.R. Differential expression of factors involved in fat metabolism with age and the menopause transition. Maturitas, 2005, 51(3), 299-306.
[http://dx.doi.org/10.1016/j.maturitas.2004.08.013] [PMID: 15978974]
[26]
Davis, S.R.; Castelo-Branco, C.; Chedraui, P.; Lumsden, M.A.; Nappi, R.E.; Shah, D.; Villaseca, P. Writing group of the international menopause society for world menopause day 2012. Understanding weight gain at menopause. Climacteric, 2012, 15(5), 419-429.
[http://dx.doi.org/10.3109/13697137.2012.707385] [PMID: 22978257]
[27]
Al-Safi, Z.A.; Polotsky, A.J. Obesity and menopause. Best Pract. Res. Clin. Obstet. Gynaecol., 2015, 29(4), 548-553.
[http://dx.doi.org/10.1016/j.bpobgyn.2014.12.002] [PMID: 25579233]
[28]
Makara-Studzińśka, M.T.; Kryś-Noszczyk, K.M.; Jakiel, G. Epidemiology of the symptoms of menopause - an intercontinental review. Przegl. Menopauz., 2014, 13(3), 203-211.
[http://dx.doi.org/10.5114/pm.2014.43827] [PMID: 26327856]
[29]
Mishra, G.D.; Kuh, D. Health symptoms during midlife in relation to menopausal transition: British prospective cohort study. BMJ, 2012, 344e402
[http://dx.doi.org/10.1136/bmj.e402] [PMID: 22318435]
[30]
Kumari, M.; Stafford, M.; Marmot, M. The menopausal transition was associated in a prospective study with decreased health functioning in women who report menopausal symptoms. J. Clin. Epidemiol., 2005, 58(7), 719-727.
[http://dx.doi.org/10.1016/j.jclinepi.2004.09.016] [PMID: 15939224]
[31]
Carol, A.; Vanessa, B.; Jo, B.; Andrea, D.; Joanne, D. Menopause and the workplace: New directions in HRM research and HR practice. Hum. Resour. Manage. J., 2020, 1-16.
[32]
Pinkerton, J.V. The NAMS 2017 hormone therapy position statement advisory panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause, 2017, 24(7), 728-753.
[http://dx.doi.org/10.1097/GME.0000000000000921] [PMID: 28650869]
[33]
Pierre-Yves, S. Postmenopausal hormone therapy and risk of venous thromboembolism: what about progesterone? BMJ, 2019, 360, 1.
[34]
Oliver-Williams, C.; Glisic, M.; Shahzad, S.; Brown, E.; Pellegrino Baena, C.; Chadni, M.; Chowdhury, R.; Franco, O.H.; Muka, T. The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review. Hum. Reprod. Update, 2019, 25(2), 257-271.
[http://dx.doi.org/10.1093/humupd/dmy039] [PMID: 30508190]
[35]
Speroff, L. Transdermal hormone therapy and the risk of stroke and venous thrombosis. Climacteric, 2010, 13(5), 429-432.
[http://dx.doi.org/10.3109/13697137.2010.507111] [PMID: 20670199]
[36]
Venetkoski, M.; Savolainen-Peltonen, H.; Rahkola-Soisalo, P.; Hoti, F.; Vattulainen, P.; Gissler, M.; Ylikorkala, O.; Mikkola, T.S. Increased cardiac and stroke death risk in the first year after discontinuation of postmenopausal hormone therapy. Menopause, 2018, 25(4), 375-379.
[http://dx.doi.org/10.1097/GME.0000000000001023] [PMID: 29112596]
[37]
Rahkola-Soisalo, P.; Savolainen-Peltonen, H.; Gissler, M.; Hoti, F.; Vattulainen, P.; Ylikorkala, O.; Mikkola, T.S. Increased risk for stress urinary incontinence in women with postmenopausal hormone therapy. Int. Urogynecol. J. Pelvic Floor Dysfunct., 2019, 30(2), 251-256.
[http://dx.doi.org/10.1007/s00192-018-3682-7] [PMID: 29946829]
[38]
Laliberté, F.; Dea, K.; Duh, M.S.; Kahler, K.H.; Rolli, M.; Lefebvre, P. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause, 2011, 18(10), 1052-1059.
[http://dx.doi.org/10.1097/gme.0b013e3182175e5c] [PMID: 21775912]
[39]
Lobo, R.A.; Pickar, J.H.; Stevenson, J.C.; Mack, W.J.; Hodis, H.N. Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. Atherosclerosis, 2016, 254, 282-290.
[http://dx.doi.org/10.1016/j.atherosclerosis.2016.10.005] [PMID: 27745704]
[40]
Prescription Drug Information, Interactions & Side Effects, 2020.https://www.drugs.com
[41]
Stevens, R.E.; Roy, R.; Phelps, K.V. Evaluation of single- and multiple-dose pharmacokinetics of synthetic conjugated estrogens, A (Cenestin) tablets: a slow-release estrogen replacement product. J. Clin. Pharmacol., 2002, 42(3), 332-341.
[http://dx.doi.org/10.1177/00912700222011256] [PMID: 11865971]
[42]
Schmidt, J.W.; Wollner, D.; Curcio, J.; Riedlinger, J.; Kim, L.S. Hormone replacement therapy in menopausal women: Past problems and future possibilities. Gynecol. Endocrinol., 2006, 22(10), 564-577.
[http://dx.doi.org/10.1080/09513590600927017] [PMID: 17135036]
[43]
Kuhl, H. Pharmacology of estrogens and progestogens: Influence of different routes of administration. Climacteric, 2005, 8(Suppl. 1), 3-63.
[http://dx.doi.org/10.1080/13697130500148875] [PMID: 16112947]
[44]
Marjoribanks, J.; Farquhar, C.; Roberts, H.; Lethaby, A.; Lee, J. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst. Rev., 2017, 1CD004143
[http://dx.doi.org/10.1002/14651858.CD004143.pub5] [PMID: 28093732]
[45]
Estrogens increase the risk of endometrial cancer. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/083220s041lbl.pdf (Accessed on April 1, 2019).
[46]
Estropipate. Available at: https://en.wikipedia.org/wiki/Estropipate (Accessed on April 1, 2019)
[47]
Prossnitz, E.R.; Barton, M. Estrogen biology: New insights into GPER function and clinical opportunities. Mol. Cell. Endocrinol., 2014, 389(1-2), 71-83.
[http://dx.doi.org/10.1016/j.mce.2014.02.002] [PMID: 24530924]
[48]
Conjugated oestrogens/bazedoxifene. Aust. Prescr., 2017, 40(3), 114-115.
[PMID: 28798519]
[49]
Foresta, C.; Zuccarello, D.; Biagioli, A.; De Toni, L.; Prana, E.; Nicoletti, V.; Ambrosini, G.; Ferlin, A. Oestrogen stimulates endothelial progenitor cells via oestrogen receptor-alpha. Clin. Endocrinol. (Oxf.), 2007, 67(4), 520-525.
[PMID: 17573901]
[50]
O’Connell, M.B. Pharmacokinetic and pharmacologic variation between different estrogen products. J. Clin. Pharmacol., 1995, 35(9S), 18S-24S.
[http://dx.doi.org/10.1002/j.1552-4604.1995.tb04143.x] [PMID: 8530713]
[51]
Rossouw, J.E.; Anderson, G.L.; Prentice, R.L.; LaCroix, A.Z.; Kooperberg, C.; Stefanick, M.L.; Jackson, R.D.; Beresford, S.A.; Howard, B.V.; Johnson, K.C.; Kotchen, J.M.; Ockene, J. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA, 2002, 288(3), 321-333.
[http://dx.doi.org/10.1001/jama.288.3.321] [PMID: 12117397]
[52]
Carani, C.; Qin, K.; Simoni, M.; Faustini-Fustini, M.; Serpente, S.; Boyd, J.; Korach, K.S.; Simpson, E.R. Effect of testosterone and estradiol in a man with aromatase deficiency. N. Engl. J. Med., 1997, 337(2), 91-95.
[http://dx.doi.org/10.1056/NEJM199707103370204] [PMID: 9211678]
[53]
Zhang, J.W.; Liu, Y.; Zhao, J.Y.; Wang, L.M.; Ge, G.B.; Gao, Y.; Li, W.; Liu, H.T.; Liu, H.X.; Zhang, Y.Y.; Sun, J.; Yang, L. Metabolic profiling and cytochrome P450 reaction phenotyping of medroxyprogesterone acetate. Drug Metab. Dispos., 2008, 36(11), 2292-2298.
[http://dx.doi.org/10.1124/dmd.108.022525] [PMID: 18725509]
[54]
Bassam, E. Non-hormonal therapies for the treatment of menopausal symptoms. Middle East Fertil. Soc. J., 2006, 11(1), 1-17.
[55]
Debra, H. Non-hormonal treatment options during the menopause. Journal of Aesthetic Nursing, 2017, 6(3), 130-135.
[http://dx.doi.org/10.12968/joan.2017.6.3.130]
[56]
Yonkers, K.A.; Gullion, C.; Williams, A.; Novak, K.; Rush, A.J. Paroxetine as a treatment for premenstrual dysphoric disorder. J. Clin. Psychopharmacol., 1996, 16(1), 3-8.
[http://dx.doi.org/10.1097/00004714-199602000-00002] [PMID: 8834412]
[57]
Miller, P.D.; Chines, A.A.; Christiansen, C.; Hoeck, H.C.; Kendler, D.L.; Lewiecki, E.M.; Woodson, G.; Levine, A.B.; Constantine, G.; Delmas, P.D. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J. Bone Miner. Res., 2008, 23(4), 525-535.
[http://dx.doi.org/10.1359/jbmr.071206] [PMID: 18072873]
[58]
Handley, A.P.; Williams, M. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review. J. Am. Assoc. Nurse Pract., 2015, 27(1), 54-61.
[http://dx.doi.org/10.1002/2327-6924.12137] [PMID: 24944075]
[59]
Kamath, J.; Handratta, V. Desvenlafaxine succinate for major depressive disorder: A critical review of the evidence. Expert Rev. Neurother., 2008, 8(12), 1787-1797.
[http://dx.doi.org/10.1586/14737175.8.12.1787] [PMID: 19086875]
[60]
Clemett, D.; Spencer, C.M. Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs, 2000, 60(2), 379-411.
[http://dx.doi.org/10.2165/00003495-200060020-00013] [PMID: 10983739]
[61]
Sturdee, D.W.; Pines, A. Updated IMS recommendations on postmenopausal hormonal therapy and preventive strategies for midlife health. Climacteric, 2011, 14, 302-320.
[62]
Shagaf, H. Bakour. Latest evidence on using hormone replacement therapy in the menopause. Obstet. Gynaecol., 2015, 17, 20-28.
[http://dx.doi.org/10.1111/tog.12155]
[63]
Taebi, M.; Abdolahian, S.; Ozgoli, G.; Ebadi, A.; Kariman, N. Strategies to improve menopausal quality of life: A systematic review. J. Educ. Health Promot., 2018, 7, 93.
[http://dx.doi.org/10.4103/jehp.jehp_137_17] [PMID: 30079364]
[64]
Wuttke, W.; Jarry, H.; Haunschild, J.; Stecher, G.; Schuh, M.; Seidlova-Wuttke, D. The non-estrogenic alternative for the treatment of climacteric complaints: Black cohosh (Cimicifuga or Actaea racemosa). J. Steroid Biochem. Mol. Biol., 2014, 139, 302-310.
[http://dx.doi.org/10.1016/j.jsbmb.2013.02.007] [PMID: 23459142]
[65]
Disch, L.; Forsch, K.; Siewert, B.; Drewe, J.; Fricker, G. in vitro and in situ characterization of triterpene glycosides from Cimicifuga racemosa extract. J. Pharm. Sci., 2017, 106(12), 3642-3650.
[http://dx.doi.org/10.1016/j.xphs.2017.07.023] [PMID: 28827038]
[66]
Alves, D.L.; Lima, S.M.; da Silva, C.R.; Galvão, M.A.; Shanaider, A.; de Almeida Prado, R.A.; Aoki, T. Effects of Trifolium pratense and Cimicifuga racemosa on the endometrium of Wistar rats. Maturitas, 2008, 61(4), 364-370.
[http://dx.doi.org/10.1016/j.maturitas.2008.08.006] [PMID: 19095386]
[67]
Powell, S.L.; Gödecke, T.; Nikolic, D.; Chen, S.N.; Ahn, S.; Dietz, B.; Farnsworth, N.R.; van Breemen, R.B.; Lankin, D.C.; Pauli, G.F.; Bolton, J.L. In vitro serotonergic activity of black cohosh and identification of N(ω)-methylserotonin as a potential active constituent. J. Agric. Food Chem., 2008, 56(24), 11718-11726.
[http://dx.doi.org/10.1021/jf803298z] [PMID: 19049296]
[68]
Nikolić, D.; Li, J.; van Breemen, R.B. Metabolism of Nω -methylserotonin, a serotonergic constituent of black cohosh (Cimicifuga racemosa, L. (Nutt.)), by human liver microsomes. Biomed. Chromatogr., 2014, 28(12), 1647-1651.
[http://dx.doi.org/10.1002/bmc.3197] [PMID: 24817649]
[69]
Hanachi, P.; Golkho, S. Assessment of soy phytoestrogens and exercise on lipid profiles and menopause symptoms in menopausal women. J. Biol. Sci., 2008, 8, 789-793.
[http://dx.doi.org/10.3923/jbs.2008.789.793]
[70]
Fattah, A. Effect of phytoestrogen on depression and anxiety in menopausal women: A systematic review. J. Menopausal Med., 2017, 23(3), 160-165.
[http://dx.doi.org/10.6118/jmm.2017.23.3.160] [PMID: 29354615]
[71]
Ehsanpour, S.; Salehi, K.; Zolfaghari, B.; Bakhtiari, S. The effects of red clover on quality of life in post-menopausal women. Iran. J. Nurs. Midwifery Res., 2012, 17(1), 34-40.
[PMID: 23493172]
[72]
van de Weijer, P.H.; Barentsen, R. Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas, 2002, 42(3), 187-193.
[http://dx.doi.org/10.1016/S0378-5122(02)00080-4] [PMID: 12161042]
[73]
Booth, N.L.; Piersen, C.E.; Banuvar, S.; Geller, S.E.; Shulman, L.P.; Farnsworth, N.R. Clinical studies of red clover (Trifolium pratense) dietary supplements in menopause: A literature review. Menopause, 2006, 13(2), 251-264.
[http://dx.doi.org/10.1097/01.gme.0000198297.40269.f7] [PMID: 16645539]
[74]
Hidalgo, L.A.; Chedraui, P.A.; Morocho, N.; Ross, S.; San Miguel, G. The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: a randomized, double-blind, placebo-controlled study. Gynecol. Endocrinol., 2005, 21(5), 257-264.
[http://dx.doi.org/10.1080/09513590500361192] [PMID: 16373244]
[75]
Nahidi, F.; Zare, E.; Mojab, F.; Alavi-Majd, H. Effects of licorice on relief and recurrence of menopausal hot flashes. Iran. J. Pharm. Res., 2012, 11(2), 541-548.
[PMID: 24250477]
[76]
Asgari, P.; Bahramnezhad, F.; Narenji, F.; Golitaleb, M.; Askari, M.A. clinical study of the effect of Glycyrrhizaglabra plant and exercise on the quality of life of menopausal women. Prev. Chronic Dis., 2015, 3(2), 79-86.
[77]
Dhingra, D.; Sharma, A. Antidepressant-like activity of Glycyrrhiza glabra L. in mouse models of immobility tests. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2006, 30(3), 449-454.
[http://dx.doi.org/10.1016/j.pnpbp.2005.11.019] [PMID: 16443316]
[78]
Simons, R.; Vincken, J.P.; Mol, L.A.; The, S.A.; Bovee, T.F.; Luijendijk, T.J.; Verbruggen, M.A.; Gruppen, H. Agonistic and antagonistic estrogens in licorice root (Glycyrrhiza glabra). Anal. Bioanal. Chem., 2011, 401(1), 305-313.
[http://dx.doi.org/10.1007/s00216-011-5061-9] [PMID: 21573846]
[79]
Budeiri, D.; Li, Wan Po A.; Dornan, J.C. Is evening primrose oil of value in the treatment of premenstrual syndrome? Control. Clin. Trials, 1996, 17(1), 60-68.
[http://dx.doi.org/10.1016/0197-2456(95)00082-8] [PMID: 8721802]
[80]
Liu, J.; Burdette, J.E.; Xu, H.; Gu, C.; van Breemen, R.B.; Bhat, K.P.; Booth, N.; Constantinou, A.I.; Pezzuto, J.M.; Fong, H.H.; Farnsworth, N.R.; Bolton, J.L. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J. Agric. Food Chem., 2001, 49(5), 2472-2479.
[http://dx.doi.org/10.1021/jf0014157] [PMID: 11368622]
[81]
Circosta, C.; Pasquale, R.D.; Palumbo, D.R.; Samperi, S.; Occhiuto, F. Estrogenic activity of standardized extract of Angelica sinensis. Phytother. Res., 2006, 20(8), 665-669.
[http://dx.doi.org/10.1002/ptr.1928] [PMID: 16691630]
[82]
Lemay, A.; Dodin, S.; Kadri, N.; Jacques, H.; Forest, J.C. Flaxseed dietary supplement versus hormone replacement therapy in hypercholesterolemic menopausal women. Obstet. Gynecol., 2002, 100(3), 495-504.
[PMID: 12220769]
[83]
Ghazanfarpour, M.; Sadeghi, R.; Abdolahian, S.; Latifnejad Roudsari, R. The efficacy of Iranian herbal medicines in alleviating hot flashes: A systematic review. Int. J. Reprod. Biomed. (Yazd), 2016, 14(3), 155-166.
[http://dx.doi.org/10.29252/ijrm.14.3.155] [PMID: 27294213]
[84]
Overk, C.R.; Guo, J.; Chadwick, L.R.; Lantvit, D.D.; Minassi, A.; Appendino, G.; Chen, S.N.; Lankin, D.C.; Farnsworth, N.R.; Pauli, G.F.; van Breemen, R.B.; Bolton, J.L. In vivo estrogenic comparisons of Trifolium pratense (red clover) Humulus lupulus (hops), and the pure compounds isoxanthohumol and 8-prenylnaringenin. Chem. Biol. Interact., 2008, 176(1), 30-39.
[http://dx.doi.org/10.1016/j.cbi.2008.06.005] [PMID: 18619951]
[85]
Aghamiri, V.; Mirghafourvand, M.; Mohammad-Alizadeh-Charandabi, S.; Nazemiyeh, H. The effect of Hop (Humulus lupulus L.) on early menopausal symptoms and hot flashes: A randomized placebo-controlled trial. Complement. Ther. Clin. Pract., 2016, 23, 130-135.
[http://dx.doi.org/10.1016/j.ctcp.2015.05.001] [PMID: 25982391]
[86]
Erkkola, R.; Vervarcke, S.; Vansteelandt, S.; Rompotti, P.; De Keukeleire, D.; Heyerick, A. A randomized, double-blind, placebo-controlled, cross-over pilot study on the use of a standardized hop extract to alleviate menopausal discomforts. Phytomedicine, 2010, 17(6), 389-396.
[http://dx.doi.org/10.1016/j.phymed.2010.01.007] [PMID: 20167461]
[87]
Bommer, S.; Klein, P.; Suter, A. First time proof of sage’s tolerability and efficacy in menopausal women with hot flushes. Adv. Ther., 2011, 28(6), 490-500.
[http://dx.doi.org/10.1007/s12325-011-0027-z] [PMID: 21630133]
[88]
Salter, S.; Brownie, S. Treating primary insomnia - the efficacy of valerian and hops. Aust. Fam. Physician, 2010, 39(6), 433-437.
[PMID: 20628685]
[89]
Mirmohammadali, M.; Zendehdel-Rakhshandeh, T.; Sadeghniiat-Haghighi, K.; Faghihzadeh, S.; Taheri, M. Evaluation of valerians’ effect on sleep quantity and quality of menopausal women: Cross-over clinical trial. Majallah-i Danishgah-i Ulum-i Pizishki-i Kirmanshah, 2014, 17, 687-697.
[90]
Taavoni, S.; Ekbatani, N.; Kashaniyan, M.; Haghani, H. Effect of valerian on sleep quality in postmenopausal women: a randomized placebo-controlled clinical trial. Menopause, 2011, 18(9), 951-955.
[http://dx.doi.org/10.1097/gme.0b013e31820e9acf] [PMID: 21775910]
[91]
Hajirahimkhan, A.; Dietz, B.M.; Bolton, J.L. Botanical modulation of menopausal symptoms: mechanisms of action? Planta Med., 2013, 79(7), 538-553.
[http://dx.doi.org/10.1055/s-0032-1328187] [PMID: 23408273]
[92]
Dietz, B.M.; Hajirahimkhan, A.; Dunlap, T.L.; Bolton, J.L. Botanicals and their bioactive phytochemicals for women’s health. Pharmacol. Rev., 2016, 68(4), 1026-1073.
[http://dx.doi.org/10.1124/pr.115.010843] [PMID: 27677719]
[93]
Contero, F. Estrogenic activity of ethanolic extracts from leaves of ilex guayusa loes. and medicago sativa in rattus norvegicus. Pharmacologyonline, 2015, 2, 95-99.
[94]
Carsten, G. Influence of Rheum rhaponticum, Cimicifuga racemosa and Trifolium pratense extracts on breast cancer cell proliferation. Z. Phytother., 2015, 36(04), 157-163.
[http://dx.doi.org/10.1055/s-0041-104301]
[95]
Singh, Y.N.; Singh, N.N. Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs, 2002, 16(11), 731-743.
[http://dx.doi.org/10.2165/00023210-200216110-00002] [PMID: 12383029]
[96]
Pittler, M.H.; Ernst, E. Efficacy of kava extract for treating anxiety: Systematic review and meta-analysis. J. Clin. Psychopharmacol., 2000, 20(1), 84-89.
[http://dx.doi.org/10.1097/00004714-200002000-00014] [PMID: 10653213]
[97]
Cheng, W.Y.; Kuo, Y.H.; Huang, C.J. Isolation and identification of novel estrogenic compounds in yam tuber (Dioscorea alata Cv. Tainung No. 2). J. Agric. Food Chem., 2007, 55(18), 7350-7358.
[http://dx.doi.org/10.1021/jf0711690] [PMID: 17685543]
[98]
Park, M.K.; Kwon, H.Y.; Ahn, W.S.; Bae, S.; Rhyu, M.R.; Lee, Y. Estrogen activities and the cellular effects of natural progesterone from wild yam extract in mcf-7 human breast cancer cells. Am. J. Chin. Med., 2009, 37(1), 159-167.
[http://dx.doi.org/10.1142/S0192415X09006746] [PMID: 19222119]
[99]
Jarry, H.; Spengler, B.; Wuttke, W.; Christoffel, V. In vitro assays for bioactivity-guided isolation of endocrine active compounds in Vitex agnus-castus. Maturitas, 2006, 55, S26-S36.
[http://dx.doi.org/10.1016/j.maturitas.2006.06.014]
[100]
Ibrahim, N.A.; Shalaby, A.S.; Farag, R.S.; Elbaroty, G.S.; Nofal, S.M.; Hassan, E.M. Gynecological efficacy and chemical investigation of Vitex agnus-castus L. fruits growing in Egypt. Nat. Prod. Res., 2008, 22(6), 537-546.
[http://dx.doi.org/10.1080/14786410701592612] [PMID: 18415863]
[101]
Kwon, J.; Oh, K.S.; Cho, S.Y.; Bang, M.A.; Kim, H.S.; Vaidya, B.; Kim, D. Estrogenic activity of hyperforin in MCF-7 human breast cancer cells transfected with estrogen receptor. Planta Med., 2016, 82(16), 1425-1430.
[http://dx.doi.org/10.1055/s-0042-112594] [PMID: 27454708]
[102]
Mi-Kyoung You. Hwa-Jin, Kim; Ji Hyun, Kook; Hyeon-A, Kim. St. John’s. Wort regulates proliferation and apoptosis in MCF-7 human breast cancer cells by inhibiting AMPK/mTOR and activating the mitochondrial pathway. Int. J. Mol. Sci., 2018, 19(4), 966.
[http://dx.doi.org/10.3390/ijms19040966]
[103]
Lee, Y.; Kim, H. Relationships between menopausal symptoms, depression, and exercise in middle-aged women: A cross-sectional survey. Int. J. Nurs. Stud., 2008, 45(12), 1816-1822.
[http://dx.doi.org/10.1016/j.ijnurstu.2008.07.001] [PMID: 18692187]
[104]
Elavsky, S. Physical activity, menopause, and quality of life: the role of affect and self-worth across time. Menopause, 2009, 16(2), 265-271.
[http://dx.doi.org/10.1097/gme.0b013e31818c0284] [PMID: 19169167]
[105]
Stojanovska, L.; Apostolopoulos, V.; Polman, R.; Borkoles, E. To exercise, or, not to exercise, during menopause and beyond. Maturitas, 2014, 77(4), 318-323.
[http://dx.doi.org/10.1016/j.maturitas.2014.01.006] [PMID: 24548848]
[106]
Mansikkamäki, K.; Raitanen, J.; Malila, N.; Sarkeala, T.; Männistö, S.; Fredman, J.; Heinävaara, S.; Luoto, R. Physical activity and menopause-related quality of life - a population-based cross-sectional study. Maturitas, 2015, 80(1), 69-74.
[http://dx.doi.org/10.1016/j.maturitas.2014.09.009] [PMID: 25449820]
[107]
Martin, C.K.; Church, T.S.; Thompson, A.M.; Earnest, C.P.; Blair, S.N. Exercise dose and quality of life: A randomized controlled trial. Arch. Intern. Med., 2009, 169(3), 269-278.
[http://dx.doi.org/10.1001/archinternmed.2008.545] [PMID: 19204218]

Rights & Permissions Print Cite
Article Metrics
21
© 2024 Bentham Science Publishers | Privacy Policy